Abstract: Peroxisome proliferator activated receptor (PPAR) compounds, and methods of using the same for treating bone fractures, treating osteoporosis and/or metabolic bone diseases, and inducing osteogenesis and/or chondrogenesis, are disclosed.

Abstract: The invention relates to methods for the preparation of a pharmaceutical-vesicle formulation comprising steps of: preparing and processing vesicle components and a pharmaceutical agent to entrap the pharmaceutical agent in the vesicle and form a pharmaceutical-vesicle formulation, wherein the pharmaceutical-vesicle formulation is reconstituted in a known quantity of the pharmaceutical agent dissolved in a pharmaceutically-acceptable carrier to provide a biphasic pharmaceutical-vesicle formulation. The invention also relates to the associated pharmaceutical-vesicle formulations, pharmaceutical kits and uses as a medicament, in particular for the prevention or treatment of infection by bacteria such as Burkholderia pseudomallei and Francisella tularensis, and viruses such as Venezuelan Equine Encephalitis Virus (VEEV).

Abstract: Systems, methods, and computer program products are provided for segmenting a brain tumor from various MRI sequencing techniques. A plurality of MRI sequences of a head of a patient are received. Each MRI sequence includes a T1-weighted with contrast image, a Fluid Attenuated Inversion Recovery (FLAIR) image, a T1-weighted image, and a T2-weighted image. Each image of the plurality of MRI sequences is registered to an anatomical atlas. A plurality of modified MRI sequences are generated by removing a skull from each image in the plurality of MRI sequences. A tumor segmentation map is determined by segmenting a tumor within a brain in each image in the plurality of modified MRI sequences. The tumor segmentation map is applied to each of the plurality of MRI sequences to thereby generate a plurality of labelled MRI sequences.

Abstract: The present disclosure provides methods of imaging cancerous cells in a subject, wherein the cancerous cells are localized to the skeletal system or central nervous system of the subject, the method comprising administering to the subject an effective amount of 18F-fluoroacetate, detecting a first signal emitted by 18F-fluoroacetate, and generating an image representative of the location and/or amount of the first signal to image the cancerous cells. In some embodiments, the methods further comprising diagnosing, prognosing, staging, and/or monitoring the progression of a disease or disorder, such as acute lymphoblastic leukemia and/or leptomeningeal disease.

Abstract: Provided herein are agents, such as antibodies, antibody-drug conjugates, or chimeric antigen receptors, that target EphA10. Methods of treating cancer are provided, comprising administering to a patient in need thereof an effective amount of an EphA10-targeting agent. The patient may be selected for treatment if the cancer expresses an increased level of EphA10.

Abstract: Provided herein are methods for predicting whether a cancer patient will respond to treatment with bevacizumab based on determining a level of small extracellular vesicle (sEV)-associated VEGF in the patient. Also provided are methods of treating patients with either bevacizumab or a VEGFR tyrosine kinase inhibitor, a VEGFR neutralizing antibody, or a VEGF ligand trap based on the level of small extracellular vesicle (sEV)-associated VEGF in the patient.

Abstract: The present disclosure provides compositions which shown preferential targeting or delivery of a nucleic acid composition to a particular organ. In some embodiments, the composition comprises a steroid or sterol, an ionizable cationic lipid, a phospholipid, a PEG lipid, and a permanently cationic lipid which may be used to deliver a nucleic acid.

Abstract: Disclosed herein are inventive methods of making thin films, inventive thin films, and inventive articles and systems comprising thin films. Certain embodiments are related to methods of making thin films in which reagents are arranged within a first phase and a second phase such that at least one reagent reacts to form a thin film proximate to the interface between the first phase and the second phase. Thin films (including two-dimensional materials) disclosed herein can have one or more of a variety of beneficial properties including large lateral dimension(s), lateral continuity, high mechanical strength, consistent spatial composition, and/or consistent thickness. In accordance with certain embodiments, thin films disclosed herein can be combined to form a variety of inventive multi-layer articles, including multi-layer articles comprising a combination of thin films having different compositions that interact with each other via van der Waals forces.

Abstract: Provided herein are methods of treating a dysmyelinating/demyelinating disease or condition in a patient in need thereof. The methods comprise restoring Qki-PPAR?-RXR?-dependent lipid metabolism in myelin. For example, the methods comprise administering a PPAR? agonist or an RXR agonist to the patient.

Abstract: Compositions that include anti-cancer, anti-tumor, and anti-microbial infection peptides are provided. In some embodiments, the compositions include 1-10 or more synthetic peptides that are between 8 and 50 amino acids long and include an amino acid sequence as disclosed herein.

Abstract: Described are methods for preparing radionuclides, such as radionuclides having a high specific activity. The disclosed methods include irradiating target nuclide materials, in solution, with a neutron source. The radionuclides can be separated from the target nuclide material by providing a solid carbon nanostructured material, as a suspension of solids, proximal to the target nuclide material in solution and using the recoil to drive adsorption of the radionuclide onto the solid carbon nanostructured material to transfer the radionuclides from the liquid phase (in solution) to the solid phase (adsorbed to the suspended solid carbon nanostructured material). One or more surfactants can be incorporated into the solution to facilitate formation of a stable suspension of the solid carbon nanostructured material.

Abstract: A method, system and computer program product for reducing the amount of helper data that needs to be stored using two innovative techniques. The first technique uses bit-error-rate (BER)-aware lossy compression. By treating a fraction of reliable bits as unreliable, it effectively reduces the size of the reliability mask. With the view of practical costs of production-time error characterization, the second technique enables economically feasible across-temperature per-bit BER evaluation for use in a number of fuzzy extractor optimizations based on bit-selection to reduce overall BER (with or without subsequent compression) using room-temperature only production-time characterization. The technique is based on stochastic concentration theory and allows efficiently forming confidence intervals for average across-temperature BER of a selected set of bits.

Abstract: The present invention relates to compounds of Formulae (I) and (II) as defined herein, and salts and solvates thereof. The present invention also relates to pharmaceutical compositions comprising compounds of Formulae (I) and (II), and to the use of compounds of Formulae (I) and (II) in the treatment or prevention of filarial worm infection, as well as other diseases or conditions in which filarial worm infection is implicated.

Abstract: Disclosed herein are nanostructured plasmonic materials. The nanostructured plasmonic materials can include a first nanostructured layer comprising: a first layer of a first plasmonic material permeated by a first plurality of spaced-apart holes, wherein the first plurality of spaced apart holes comprise a first array; and a second nanostructured layer comprising a second layer of a second plasmonic material permeated by a second plurality of spaced-apart holes, wherein the second plurality of spaced apart holes comprise a second array; wherein the second nanostructured layer is located proximate the first nanostructured layer; and wherein the first principle axis of the first array is rotated at a rotation angle compared to the first principle axis of the second array.

Abstract: The present invention provides novel methods and compositions for use in preventing infection with at least one type of influenza virus, including the use of peptides or compositions comprising a peptide comprising, consisting or consisting essentially of an amino acid sequence selected from the group of sequences as shown in SEQ ID Nos: 1 to 53, or functional derivatives or homologues thereof.

Abstract: The present application relates to the treatment of nematode infections.

Abstract: Disclosed are air-stable small-molecule adsorbents trimeric [Cu—Br]3 and [Cu—H]3 that undergo a reversible solid-state molecular rearrangements to [Cu—Br.(alkene)]2 and [Cu—H.(alkene)]2 dimers. The reversible solid-state rearrangement allows one to break adsorbent design trade-offs and achieve low heat of adsorption while retaining high selectivity and uptake.

Abstract: Antibodies exhibiting a specific genetically modified signature associated with certain diseases of the central nervous system, like multiple sclerosis (MS) and clinically isolated syndrome have been identified. These antibodies recognize and bind with certain tissues in the brain and central nervous system and thus are useful as therapeutics, in the production of animal disease models, targets for therapies and as part of assays of the central nervous system.

Abstract: The present disclosure provides methods of treating cancer in a patient determined to have a p53 mutation by administering an inhibitor of nonsense mediated decay. The patient may be further administered an inhibitor of mRNA splicing and/or an inhibitor of MDM.

Abstract: Provided herein are DNA aptamers targeting AXL receptor kinase. The DNA aptamers may comprise a thiophosphate backbone and be chemically modified. Further provided herein are methods of use thereof for the treatment of a disease or disorder, such as cancer.